Characterization of Type 2 Diabetes Subgroups at Diagnosis: a Necessary Step Towards Precision Medicine in Diabetes. (COPERNICAN)
Caracterización de Subgrupos de Diabetes Tipo 2 al diagnóstico: un Paso Necesario Hacia la Medicina de precisión en Diabetes.
Objectives: The primary objective is to identify and characterize the relevant subgroups ( clusters ) in type 2 diabetes (T2DM) at the time of diagnosis in our region. This objective will be addressed using the six main variables (see Methodology) used so far in previous studies in other populations to develop the clustering of diabetes. Therefore, this is a study in diagnostic precision medicine in diabetes. In addition, as secondary objectives, other phenotypic characteristics of these subgroups (clinical, metabolic, and associated comorbidities) will be evaluated.
Methodology: This project will establish a prospective observational cohort study of 1200 subjects newly diagnosed with T2DM in primary care centers in the healthcare areas of Barcelona city and the territory of Lleida. All newly diagnosed cases of T2DM will be identified and evaluated. Participants will undergo a comprehensive phenotypic evaluation, including the six variables that will allow the characterization of T2DM subgroups: age, antibodies against glutamic acid decarboxylase (GAD), body mass index, glycated hemoglobin, and sensitivity indices ( HOMA-IR) and insulin secretion (HOMA beta), based on the determination of C-peptide. The latest generation cluster analysis (k- means and hierarchical clustering ) will be performed, following the method described in previous studies using the six variables mentioned above. Onset diabetes subgroups and their association with secondary outcome variables will be assessed. The initial prescription of antidiabetic medication will be evaluated. Other procedures of this project include: clinical (including complications) and biochemical evaluation, advanced lipoprotein profile, and validated questionnaires to evaluate diet and physical activity.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
A multicenter prospective observational study will be conducted. The study design contemplates a single visit that will coincide with the inclusion of the patient in the study. Prior to the inclusion visit, a pre-selection period is planned in which the possible candidate will be invited, all the study procedures will be explained and clarified, the selection criteria will be checked and the inclusion visit will be scheduled.
The scope of the study is made up of Primary Care Centers (CAP) in 2 large health areas (Barcelona and Lleida). In the Annex 8 section, the characteristics and expected recruitment capacity of each CAP are detailed. We have taken a conservative approach using the lower range of incidence calculated based on our own data from 2019 to 2020. The table provided used an expected acceptance rate for participation of 80%. Additionally, CAPs were selected based on commitment and performance in our previous studies. It is planned to include 1200 participants newly diagnosed with T2DM. Depending on compliance with the recruitment rate, the inclusion of other CAPs is possible to achieve the expected number of participants in the study.
Follow-up of participants and linkage with other databases
For this study, a pragmatic follow-up of the participants will be chosen, which is adapted to the usual clinical practice for the follow-up of diabetes. For this reason, the monitoring will be done from:
- SIDIAP/PADRIS databases, with the link to the electronic medical record of the participants who have accepted this option in the informed consent.
- Electronic medical record, in the event that the link with the SIDIAP/PADRIS databases is not possible for technical reasons (non-ICS centers), the collection of monitoring variables will be done directly from the clinical course (review of clinical history) of participants without scheduling additional study follow-up visits.
- For specific causes of mortality, data linkage with the National Institute of Statistics (INE) will be used.
- If the participants have already participated or are participating in other clinical research studies and want to transfer the data they have provided for other projects to this study, this linking (portability) of the data will be allowed.
All participants will be followed until the end of the study, death or withdrawal of informed consent.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Dídac Mauricio, MD, PhD
- Número de teléfono: +34935565661
- Correo electrónico: dmauricio@santpau.cat
Copia de seguridad de contactos de estudio
- Nombre: Bogdan Vlacho, PharmD
- Número de teléfono: +34 93 207 37 60
- Correo electrónico: bvlacho@santpau.cat
Ubicaciones de estudio
-
-
Catalunya
-
Barcelona, Catalunya, España, 08025
- Aún no reclutando
- Hospital of Santa Creu i Sant Pau
-
Contacto:
- Didac Mauricio, MD, PhD
-
Barcelona, Catalunya, España, 08025
- Reclutamiento
- Institut Català de la Salut
-
Contacto:
- Josep Franch-Nadal, MD,PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Subjects of both sexes, of legal age (≥18 years)
- Newly diagnosed T2DM according to the criteria of the American Diabetes Association
- With a maximum duration of three months of the disease at the time of inclusion.
- Writen informed consent
Exclusion Criteria:
Subjects with a new diagnosis of other types of diabetes (type 1, MODY, gestational or other causes) will also be evaluated to ensure that the diagnostic criteria for selection are correctly implemented in all potential study participants.
*For final analysis, subjects with any diagnosis of diabetes other than T2DM will be excluded from the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Newly diagnosed T2DM
To assess and characterize the relevant subgroups (clusters) of type 2 diabetes at diagnosis in our population. This objective will be addressed using the 6 main variables that have been used so far in previous studies in other populations to develop disease groupings, that is, age, GAD antibodies, body mass index, glycosylated hemoglobin (HbA1c), and estimates of the evaluation of the homeostatic model 2 of β-cell function and insulin resistance. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
clusters of type 2 diabetes
Periodo de tiempo: at inclusion
|
To assess and characterize the relevant subgroups (clusters) of type 2 diabetes at diagnosis in our population
|
at inclusion
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
gender clinical characteristics
Periodo de tiempo: at inclusion
|
To assess if there are gender diferences among the type 2 diabetes persons at diagnosis
|
at inclusion
|
|
Frequency of various associated comorbidities, including micro and macrovascular complications
Periodo de tiempo: 24 month follow-up period
|
To evaluate and describe the complications of type 2 diabetes during the 24 month follow-up period
|
24 month follow-up period
|
|
Advanced lipoprotein profile
Periodo de tiempo: at inclusion
|
to explore and characterize the lipoprotein profile of the persons with type 2 diabetes at diagnosis
|
at inclusion
|
|
Lifestyle variables: eating habits and physical activity
Periodo de tiempo: at inclusion
|
to explore if there are differences in lifestyle variables such as eating habits and physical activity at diagnosis of type 2 Diabetes Mellitus
|
at inclusion
|
|
Use in real clinical practice of antidiabetics and other treatments at the beginning of the disease
Periodo de tiempo: at inclusion
|
to explore if there are differences in treatment of the antidiabetic drugs and other concomitant medications at diagnosis of type 2 Diabetes Mellitus
|
at inclusion
|
|
Appearance of different micro- and macro-vascular complications of diabetes
Periodo de tiempo: 24 month follow-up period
|
to explore if there are differences in micro and macrovascular complications during the follow-up period related to different sub-types of type 2 Diabetes Mellitus
|
24 month follow-up period
|
|
Metabolomics and genetic profile related to diabetes
Periodo de tiempo: at inclusion
|
to explore if there are differences in Metabolomics and genetic profile related to different sub-types of type 2 Diabetes Mellitus at diagnosis
|
at inclusion
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Dídac Mauricio, MD, PhD, Hospital of Santa Creu i Sant Pau
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IIBSP-CDM- 2021-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .